Third, RG7388 demonstrated multi-modal anti-tumor activity by: (1) degrading mutant p53 and EGFR, (2) remodeling the inflammatory TME through pyroptosis-induced immunomodulation [20, 53] and (3) activating oxidative stress-dependent death pathways. This evidence concerns the gene TP53 and neoplasm.